Post-Hoc Analysis of Potential Correlates of Protection of a Recombinant SARS-CoV-2 Spike Protein Extracellular Domain Vaccine Formulated with Advax-CpG55.2-Adjuvant

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Sep 14

PMID 39273405

Authors

Nikolai Petrovsky

Affiliations

Soon will be listed here.

Abstract

SpikoGen vaccine is a subunit COVID-19 vaccine composed of an insect cell expressed recombinant spike protein extracellular domain formulated with Advax-CpG55.2™ adjuvant. A randomized double-blind, placebo-controlled Phase II clinical trial was conducted in 400 adult subjects who were randomized 3:1 to receive two intramuscular doses three weeks apart of either SpikoGen vaccine 25 μg or saline placebo, as previously reported. This study reports a post hoc analysis of the trial data to explore potential immune correlates of SpikoGen vaccine protection. A range of humoral markers collected pre- and post-vaccination, including spike- and RBD-binding IgG and IgA, surrogate (sVNT), and conventional (cVNT) virus neutralization tests were compared between participants who remained infection-free or got infected over three months of follow-up. From 2 weeks after the second vaccine dose, 21 participants were diagnosed with SARS-CoV-2 infection, 13 (4.2%) in the SpikoGen group and 8 (9%) in the placebo group. Those in the vaccinated group who experienced breakthrough infections had significantly lower sVNT titers (GMT 5.75 μg/mL, 95% CI; 3.72-8.91) two weeks after the second dose (day 35) than those who did not get infected (GMT 21.06 μg/mL, 95% CI; 16.57-26.76). Conversely, those who did not develop SARS-CoV-2 infection during follow-up had significantly higher baseline sVNT, cVNT, spike-binding IgG and IgA, and RBD-binding IgG, consistent with a past SARS-CoV-2 infection. SpikoGen further reduced the risk of re-infection (OR 0.29) in baseline seropositive (previously infected) as well as baseline seronegative participants. This indicates that while SpikoGen vaccine is protective in seronegative individuals, those with hybrid immunity have the most robust protection.

References

Honda-Okubo Y, Bowen R, Barker M, Bielefeldt-Ohmann H, Petrovsky N . Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants. Vaccine. 2023; 41(48):7116-7128. PMC: 10873063. DOI: 10.1016/j.vaccine.2023.10.018. View

Shrestha N, Burke P, Nowacki A, Gordon S . Risk of Coronavirus Disease 2019 (COVID-19) among those up-to-date and not up-to-date on COVID-19 vaccination by US CDC criteria. PLoS One. 2023; 18(11):e0293449. PMC: 10631626. DOI: 10.1371/journal.pone.0293449. View

McPherson C, Chubet R, Holtz K, Honda-Okubo Y, Barnard D, Cox M . Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant. Methods Mol Biol. 2016; 1403:269-84. PMC: 7139448. DOI: 10.1007/978-1-4939-3387-7_14. View

Goldblatt D, Fiore-Gartland A, Johnson M, Hunt A, Bengt C, Zavadska D . Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine. 2021; 40(2):306-315. PMC: 8673730. DOI: 10.1016/j.vaccine.2021.12.006. View

Tabarsi P, Anjidani N, Shahpari R, Mardani M, Sabzvari A, Yazdani B . Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial. Clin Microbiol Infect. 2022; 29(2):215-220. PMC: 9463077. DOI: 10.1016/j.cmi.2022.09.001. View

Zhang L, Lepenies B, Nakamae S, Young B, Santos R, Raffatellu M . The Vi Capsular Polysaccharide of Salmonella Typhi Promotes Macrophage Phagocytosis by Binding the Human C-Type Lectin DC-SIGN. mBio. 2022; 13(6):e0273322. PMC: 9765441. DOI: 10.1128/mbio.02733-22. View

Honda-Okubo Y, Barnard D, Ong C, Peng B, Tseng C, Petrovsky N . Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J Virol. 2014; 89(6):2995-3007. PMC: 4337527. DOI: 10.1128/JVI.02980-14. View

Petrovsky N . Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine. Hum Vaccin Immunother. 2024; 20(1):2363016. PMC: 11155708. DOI: 10.1080/21645515.2024.2363016. View

Irrgang P, Gerling J, Kocher K, Lapuente D, Steininger P, Habenicht K . Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci Immunol. 2022; 8(79):eade2798. PMC: 9847566. DOI: 10.1126/sciimmunol.ade2798. View

10.

Siller A, Seekircher L, Wachter G, Astl M, Tschiderer L, Pfeifer B . Seroprevalence, Waning and Correlates of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of 35,193 Blood Donors Conducted between June 2020 and September 2021. Viruses. 2022; 14(3). PMC: 8954543. DOI: 10.3390/v14030568. View

11.

Beirag N, Kumar C, Madan T, Shamji M, Bulla R, Mitchell D . Human surfactant protein D facilitates SARS-CoV-2 pseudotype binding and entry in DC-SIGN expressing cells, and downregulates spike protein induced inflammation. Front Immunol. 2022; 13:960733. PMC: 9367475. DOI: 10.3389/fimmu.2022.960733. View

12.

Krammer F, Srivastava K, Alshammary H, Amoako A, Awawda M, Beach K . Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med. 2021; 384(14):1372-1374. PMC: 8008743. DOI: 10.1056/NEJMc2101667. View

13.

Tabarsi P, Anjidani N, Shahpari R, Roshanzamir K, Fallah N, Andre G . Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trial. Immunology. 2022; 167(3):340-353. PMC: 9349507. DOI: 10.1111/imm.13540. View

14.

Baldwin J, Piplani S, Sakala I, Honda-Okubo Y, Li L, Petrovsky N . Rapid development of analytical methods for evaluating pandemic vaccines: a COVID-19 perspective. Bioanalysis. 2021; 13(24):1805-1826. PMC: 8516068. DOI: 10.4155/bio-2021-0096. View

15.

Murad Y, Clay T . CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer. BioDrugs. 2009; 23(6):361-75. DOI: 10.2165/11316930-000000000-00000. View

16.

Jaganathan S, Stieber F, Rao S, Nikolayevskyy V, Manissero D, Allen N . Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals. Infect Dis Ther. 2021; 10(4):2765-2776. PMC: 8386336. DOI: 10.1007/s40121-021-00521-8. View

17.

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615. PMC: 7745181. DOI: 10.1056/NEJMoa2034577. View

18.

Pal R, Ferrari M, Honda-Okubo Y, Wattay L, Caple J, Navarrete J . Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates. Vaccine. 2024; 42(5):1122-1135. DOI: 10.1016/j.vaccine.2024.01.034. View

19.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

20.

Shrestha N, Burke P, Nowacki A, Simon J, Hagen A, Gordon S . Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine. Open Forum Infect Dis. 2023; 10(6):ofad209. PMC: 10234376. DOI: 10.1093/ofid/ofad209. View